Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W.

Cancer Discov. 2012 Sep;2(9):791-7. Epub 2012 Jul 13.

2.

The role of MEK inhibitors in the treatment of metastatic melanoma.

Grimaldi AM, Simeone E, Ascierto PA.

Curr Opin Oncol. 2014 Mar;26(2):196-203. doi: 10.1097/CCO.0000000000000050. Review.

PMID:
24419498
3.

Trametinib (GSK1120212) in the treatment of melanoma.

Salama AK, Kim KB.

Expert Opin Pharmacother. 2013 Apr;14(5):619-27. doi: 10.1517/14656566.2013.770475. Epub 2013 Feb 23. Review.

PMID:
23432625
4.

Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.

King JW, Nathan PD.

Future Oncol. 2014;10(9):1559-70. doi: 10.2217/fon.14.89. Review.

PMID:
25145427
5.

BRAF somatic mutations in malignant melanoma and melanocytic naevi.

Thomas NE.

Melanoma Res. 2006 Apr;16(2):97-103. Review.

PMID:
16567964
6.

Resistance to BRAF-targeted therapy in melanoma.

Sullivan RJ, Flaherty KT.

Eur J Cancer. 2013 Apr;49(6):1297-304. doi: 10.1016/j.ejca.2012.11.019. Epub 2013 Jan 2. Review.

PMID:
23290787
7.

MEK inhibition in the treatment of advanced melanoma.

Salama AK, Kim KB.

Curr Oncol Rep. 2013 Oct;15(5):473-82. doi: 10.1007/s11912-013-0336-2. Review.

PMID:
23975010
8.

MAP kinase signaling and inhibition in melanoma.

Sullivan RJ, Flaherty K.

Oncogene. 2013 May 9;32(19):2373-9. doi: 10.1038/onc.2012.345. Epub 2012 Sep 3. Review.

PMID:
22945644
9.

Trametinib in the treatment of melanoma.

Thota R, Johnson DB, Sosman JA.

Expert Opin Biol Ther. 2015 May;15(5):735-47. doi: 10.1517/14712598.2015.1026323. Epub 2015 Mar 26. Review.

PMID:
25812921
10.

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

Nissan MH, Solit DB.

Curr Oncol Rep. 2011 Dec;13(6):479-87. doi: 10.1007/s11912-011-0198-4. Review.

PMID:
21997758
11.

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.

Queirolo P, Picasso V, Spagnolo F.

Cancer Treat Rev. 2015 Jun;41(6):519-26. doi: 10.1016/j.ctrv.2015.04.010. Epub 2015 Apr 29. Review.

PMID:
25944484
12.

Targeted therapies for cutaneous melanoma.

Kee D, McArthur G.

Hematol Oncol Clin North Am. 2014 Jun;28(3):491-505. doi: 10.1016/j.hoc.2014.02.003. Epub 2014 Apr 3. Review.

PMID:
24880943
13.

Targeting BRAF in melanoma: biological and clinical challenges.

MandalĂ  M, Voit C.

Crit Rev Oncol Hematol. 2013 Sep;87(3):239-55. doi: 10.1016/j.critrevonc.2013.01.003. Epub 2013 Feb 15. Review.

PMID:
23415641
14.

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

Luke JJ, Hodi FS.

Oncologist. 2013 Jun;18(6):717-25. doi: 10.1634/theoncologist.2012-0391. Epub 2013 May 24. Review.

15.

Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.

Jang S, Atkins MB.

Clin Pharmacol Ther. 2014 Jan;95(1):24-31. doi: 10.1038/clpt.2013.197. Epub 2013 Sep 30. Review.

PMID:
24080641
16.

BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.

Richman J, Martin-Liberal J, Diem S, Larkin J.

Expert Opin Pharmacother. 2015 Jun;16(9):1285-97. doi: 10.1517/14656566.2015.1044971. Review.

PMID:
26001180
17.

MEK and RAF inhibitors for BRAF-mutated cancers.

Belden S, Flaherty KT.

Expert Rev Mol Med. 2012 Oct 12;14:e17. doi: 10.1017/erm.2012.11. Review.

PMID:
23058743
18.

Targeted Therapy for Melanoma.

Wong DJ, Ribas A.

Cancer Treat Res. 2016;167:251-62. doi: 10.1007/978-3-319-22539-5_10. Review.

PMID:
26601866
19.

Biological challenges of BRAF inhibitor therapy.

Puzanov I, Burnett P, Flaherty KT.

Mol Oncol. 2011 Apr;5(2):116-23. doi: 10.1016/j.molonc.2011.01.005. Epub 2011 Feb 16. Review.

20.

Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.

Chung C, Reilly S.

Am J Health Syst Pharm. 2015 Jan 15;72(2):101-10. doi: 10.2146/ajhp140045. Review.

PMID:
25550132
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk